We are proud to anounce that our spin-off company GlyCardial Diagnostics has received the SME instrument phase II funding of the H2020 programme to advance in the development of our novel test for the early detection of cardiac ischemia in their first trial. It is highly motivating to see that the EU trusts in young and innovative projects.
